Neuroimaging of Schizophrenia and Other Primary Psychotic Disorders -

Neuroimaging of Schizophrenia and Other Primary Psychotic Disorders

Achievements and Perspectives
Buch | Hardcover
X, 345 Seiten
2019 | 1st ed. 2019
Springer International Publishing (Verlag)
978-3-319-97306-7 (ISBN)
128,39 inkl. MwSt

This book presents the state of the art in the use of neuroimaging technologies in the study of schizophrenia and other primary psychotic disorders. The contributions of neuroimaging in the characterization of these disorders are reviewed across diagnoses, by focusing on psychopathological domains and at-risk populations in order to understand the implications for treatment. The principal neuroimaging findings are described in detail, identifying those that are common to and specific for each disorder and highlighting important pitfalls.  Attention is drawn to potential translational aspects of research in the field, with discussion of emerging innovative perspectives.

Neuroimaging research has shown that abnormalities of brain structure and function associated with psychiatric disorders do not reflect the boundaries of current diagnostic categories. However, neuroimaging findings are being reconsidered in the light of recent research proposals aimed at re-conceptualizingclassification systems in Psychiatry. Written by leading experts, this book will appeal to all with an interest in the field, including researchers, clinicians, and trainees.

Silvana Galderisi is full professor of Psychiatry and Director of the Training School in Psychiatry at the University of Campania Luigi Vanvitelli. She is the Director of the Emergency Unit of the Department of Mental Health of the same University; Coordinator of the Outpatient Unit for Anxiety and Psychotic Disorders and of the Rehabilitation Program for severe mental disorders of the same Department. She is President of the European Psychiatric Association (EPA), Chairperson of the Neuroimaging Section of the World Psychiatric Association (WPA), of the EPA Schizophrenia Section, and of the European College of NeuroPsychopharmacology (ECNP) Schizophrenia Network. She is founding member and member of the Board of Directors of the European Group for Research in Schizophrenia; board member of the Schizophrenia International Research Society (SIRS), of the European Scientific Association on Schizophrenia (ESAS), of the Italian Society for Psychopathology and Italian Society of Biological Psychiatry. She has also served as President of the International Society for Brain Electromagnetic Topography and President of the EEG & Clinical Neuroscience Society. She is Honorary Member of the World Psychiatric Association-WPA, and International Distinguished Fellow of the American Psychiatric Association-APA.  She is author/coauthor of more than 200 publications, in national and international journals and books, and member of the Editorial Boards of several international psychiatric journals.Dr. DeLisi is currently an Attending Psychiatrist in the VA Boston Healthcare System and Professor of Psychiatry at Harvard Medical School. In addition, she has been Editor-in-Chief and co-founder of the Schizophrenia Research journal from the mid 1980's until 2017. Beginning January, 2019 she will be editor-in-chief of the journal Psychiatry Research.  She was secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS) and The International Society of Psychiatric Genetics (ISPG) and is currently president of SIRS. Dr DeLisi was the first to conduct a longitudinal controlled MRI study that showed progressive brain change in schizophrenia and was a pioneer in developing an international collaboration for ascertainment of families with multiple members having schizophrenia to participate in molecular genetic studies. From 2001 through 2008 she was professor at New York University School of Medicine and Associate Director of the brain imaging division at The Nathan Kline Institute for Psychiatric Research where she contributed several studies on anomalies of language processing in people at high risk for schizophrenia. She moved to her current position in the Boston area in January 2009 where she continues to focus her research on biological markers for high risk for schizophrenia and the effects of marijuana on adolescents. Dr DeLisi edited and authored over 300 books and manuscripts and aside from editing her own journal, serves on the editorial board of several other journals.Stefan Borgwardt is a Professor of Neuropsychiatry in the Department of Psychiatry, University of Basel, Switzerland. He is Head Physician at the Psychiatric University Hospital (UPK), Basel, where he also heads the Neuropsychiatry and Brain Imaging research group.  Dr. Borgwardt graduated from the Charité Medical School, Berlin and trained in psychiatric practice and research methodology in Basel, subsequently becoming a clinical research fellow at the Institute of Psychiatry, King´s College London, where he is now a Visiting Professor. He is also Secretary of the Section of Neuroimaging of the World Psychiatric Association (WPA). His research interests include structural and functional neuroimaging, pharmacological neuroimaging methods, and neurocognitive and genetic mechanisms in schizophrenia.  

Neuroimaging and diagnostic boundaries/biomarkers (S. Galderisi, L. DeLisi).- Neuroimaging and psychopathological domains (A. Mucci, S, Galderisi, T. Dierks): Positive symptoms.  Negative symptoms. Psychomotor Symptoms. Thought/language disorders.- Neuroimaging, neurodevelopmental and neurodegenerative features(S. Borgwardt, L. DeLisi, A. Heinz).- Neuroimaging and neurotransmitters (S. Borgwardt, L. DeLisi, A. Heinz).- Neuroimaging and genetics (S. Borgwardt, L. DeLisi, A. Heinz).- Neuroimaging and longitudinal course (G. Busatto, P. Fusar Poli, L. DeLisi).- Neuroimaging and At Risk States (P. Fusar Poli, S. Borgwardt).- Neuroimaging and antipsychotics (A. Vita).- Research perspectives for Neuroimaging of Schizophrenia spectrum disorders (S. Borgwardt, P. Fusar Poli, A. Heinz).- Toward clinical translation of Neuroimaging research in Schizophrenia and other primary psychotic disorders (S. Galderisi, L. DeLisi)

"I was personally very interested in reading the book, which well represents the state of the art and perspectives on the subject, and also indicates the tools for further studies in the updated and voluminous bibliography. Therefore, I recommend this publication at first to psychiatrists, clinicians, and researchers in neurosciences, clearly including residents and students in the field. ... it is a great field of knowledge development that this book invites us to face." (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46 (10), 2019)

“I was personally very interested in reading the book, which well represents the state of the art and perspectives on the subject, and also indicates the tools for further studies in the updated and voluminous bibliography. Therefore, I recommend this publication at first to psychiatrists, clinicians, and researchers in neurosciences, clearly including residents and students in the field. … it is a great field of knowledge development that this book invites us to face.” (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46 (10), 2019)

Erscheinungsdatum
Zusatzinfo X, 345 p. 35 illus., 22 illus. in color.
Verlagsort Cham
Sprache englisch
Maße 155 x 235 mm
Gewicht 620 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
Schlagworte brain imaging • Clinical translation • Longitudinal course • Neuroimaging findings • neurotransmitters • Pathophysiology of schizophrenia • psychotic disorders • Schizophrenia spectrum disorders • Transnosographic approach
ISBN-10 3-319-97306-1 / 3319973061
ISBN-13 978-3-319-97306-7 / 9783319973067
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Menschen mit psychischer Erkrankung wirksam unterstützen

von Matthias Hammer; Irmgard Plößl

Buch | Hardcover (2023)
Psychiatrie Verlag
35,00